Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Nicotinamide Phosphoribosyltransferase pipeline drugs market research report outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.

Visfatin Pipeline Drugs Market by Key Therapy Areas

The key therapy areas in the Visfatin pipeline drugs market are oncology, infectious disease, toxicology, cardiovascular, central nervous system, gastrointestinal, immunology, and respiratory.

Visfatin Pipeline Drugs Market, by Therapy Areas

Visfatin Pipeline Drugs Market, by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanism of Actions in the Visfatin Pipeline Drugs Market

The key mechanism of actions of the Visfatin pipeline drugs market are Nicotinamide Phosphoribosyltransferase Inhibitor and Nicotinamide Phosphoribosyltransferase Activator.

Visfatin Pipeline Drugs Market, by Mechanism of Actions

Visfatin Pipeline Drugs Market, by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Visfatin Pipeline Drugs Market

The key routes of administration in the Visfatin pipeline drugs market are oral and intravenous.

Visfatin Pipeline Drugs Market, by Routes of Administration

Visfatin Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Visfatin Pipeline Drugs Market

The key molecule types in the Visfatin pipeline drugs market are small molecule and monoclonal antibody.

Visfatin Pipeline Drugs Market, by Molecule Types

Visfatin Pipeline Drugs Market, by Molecule Types

For more molecule types insights, download a free report sample

Key Companies in the Visfatin Pipeline Drugs Market

The key companies in the Visfatin pipeline drugs market are AbbVie Inc, Aqualung Therapeutics Corp, Aurigene Discovery Technologies Ltd, Calico Life Sciences LLC, Eli Lilly and Co, Genentech USA Inc, Karyopharm Therapeutics Inc, OncoTartis Inc, Remedy Plan Inc, Tianjin Hemay Pharmaceutical Co Ltd, and Valo Health LLC.

Visfatin Pipeline Drugs Market, by Companies

Visfatin Pipeline Drugs Market, by Companies

To know more about the companies, download a free report sample

Nicotinamide Phosphoribosyltransferase Pipeline Drugs Market Report Overview

Key Therapy Areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System, Gastrointestinal, Immunology, and Respiratory
Key Mechanism of Actions Nicotinamide Phosphoribosyltransferase Inhibitor and Nicotinamide Phosphoribosyltransferase Activator
Key Routes of Administration Oral and Intravenous
Key Molecule Types Small Molecule and Monoclonal Antibody
Key Companies AbbVie Inc, Aqualung Therapeutics Corp, Aurigene Discovery Technologies Ltd, Calico Life Sciences LLC, Eli Lilly and Co, Genentech USA Inc, Karyopharm Therapeutics Inc, OncoTartis Inc, Remedy Plan Inc, Tianjin Hemay Pharmaceutical Co Ltd, and Valo Health LLC

Scope

This report provides:

  • A snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12).
  • Reviews of targeted therapeutics for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) therapeutics and enlists all their major and minor projects.
  • Assessment of Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summarization of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics.

Reasons to Buy

  • Gain strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

AbbVie Inc
Aqualung Therapeutics Corp
Aurigene Discovery Technologies Ltd
Calico Life Sciences LLC
Eli Lilly and Co
Genentech USA Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Remedy Plan Inc
Tianjin Hemay Pharmaceutical Co Ltd
Valo Health LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Companies Involved in Therapeutics Development

AbbVie Inc

Aqualung Therapeutics Corp

Aurigene Discovery Technologies Ltd

Calico Life Sciences LLC

Eli Lilly and Co

Genentech USA Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Remedy Plan Inc

Tianjin Hemay Pharmaceutical Co Ltd

Valo Health LLC

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Drug Profiles

ALT-200 – Drug Profile

Product Description

Mechanism Of Action

AU-4869 – Drug Profile

Product Description

Mechanism Of Action

History of Events

enamptcumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

GNE-617 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Hemay-088 – Drug Profile

Product Description

Mechanism Of Action

KPT-9274 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LSN-3154567 – Drug Profile

Product Description

Mechanism Of Action

OPL-0021 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OT-82 – Drug Profile

Product Description

Mechanism Of Action

History of Events

P7-C3A20 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RP-216 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit NAMPT for Oncology – Drug Profile

Product Description

Mechanism Of Action

STF-118804 – Drug Profile

Product Description

Mechanism Of Action

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) – Product Development Milestones

Featured News & Press Releases

Apr 04, 2022: Aqualung Therapeutic’s ALT-100 monoclonal antibody cited as a novel therapeutic for lung fibrosis

Feb 01, 2022: Aqualung Therapeutic’s ALT-100 antibody significantly reduces ARDS severity in both rat and porcine (large animal) preclinical models

Jan 25, 2022: Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

Dec 07, 2021: CEO & Founder of Aqualung Therapeutics Joe G.N. Garcia MD to present corporate update at the Annual Biotech Showcase in San Francisco

Aug 23, 2021: Aqualung Therapeutics selected to present at the Phoenix 2021 Venture Madness Competition on October 6-7th

Jun 15, 2021: Aqualung Therapeutics plans A phase 0 ARDS trial for eNAMPT monoclonal antibody (Alt-100 mAb) following Type B FDA meeting

Apr 05, 2021: Antengene announces NMPA approval of IND application for ATG-019 in patients with advanced solid tumors or non-Hodgkin’s lymphoma

Feb 11, 2021: eNAMPT, the inflammation-regulatory protein specifically targeted by aqualung therapeutic’s monoclonal antibody ALT-100, is now tightly linked to outcomes in COVID-19 infected patients

Dec 02, 2020: Aqualung Therapeutics publication supports eNAMPT as both biomarker & therapeutic target in prostate cancer; prostate cancer KOL new addition to scientific advisory board

Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury

Jun 02, 2020: Aqualung Therapeutics receives A $2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury

May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill

Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin’s lymphoma

Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)

Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Aqualung Therapeutics Corp, 2022

Pipeline by Aurigene Discovery Technologies Ltd, 2022

Pipeline by Calico Life Sciences LLC, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Genentech USA Inc, 2022

Pipeline by Karyopharm Therapeutics Inc, 2022

Pipeline by OncoTartis Inc, 2022

Pipeline by Remedy Plan Inc, 2022

Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022

Pipeline by Valo Health LLC, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.